IFN-β, the most frequently used first-line treatment for relapsing-remitting MS, has antiviral and immunoregulatory activities and reduces relapse frequency and brain MRI activity in relapsing-remitting MS patients [41]. Here, IFNB1 is linked to relapsing-remitting multiple sclerosis.